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Summary Objective: The current recommended inactivating agent for the rabies
virus, beta propiolactone (BPL) is very expensive and potentially carcinogenic. There
is a need to evaluate alternative chemicals, which will inactivate the virus without
affecting its antigenicity. In this study the effect of ascorbic acid on the infectivity
of the rabies virus has been investigated.
Method: Vero cell grown ﬁxed rabies virus CVS strain was treated with 0.1mg/ml,
0.5mg/ml and 1mg/ml ﬁnal concentrations of ascorbic acid and 5g/ml of copper
sulfate and kept at 4 ◦C along with untreated virus material. Each aliquot was titrated
after various intervals for viral infectivity using both mice inoculation and titration in
vero cells. The antigenicity of the virus material was determined by antibody induction
in mice and modiﬁed NIH tests in parallel with virus material inactivated with a 1:4000
concentration of BPL.
Results: An optimal concentration of 0.5mg/ml of ascorbic acid and 5g/ml of
copper sulfate completely inactivated the virus after 72 hours. The inactivated virus
retained good antigenicity and potency value, which was comparable with using BPL.
Conclusion: These ﬁndings suggest that ascorbic acid can be used as an inactivating
agent for ﬁxed rabies virus grown in cell culture particularly for the preparation of
diagnostic reagents. Further studies are required to evaluate its effect on the cell
associated virus, probable therapeutic potential and feasibility of replacing BPL in
production of inactivated rabies vaccine.
© 2003 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Introduction
The rabies virus is a single stranded negative sense
RNA virus belonging to the genus Lyssavirus of the
family Rhabdoviridae. The virus causes fatal en-
cephalitis both in humans and animals, which is
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still a major public health problem in developing
countries in Asia, Africa and Latin America. Around
50,000 human deaths are still reported world-wide,
mostly from the Indian subcontinent.1 Rabies is
also re-emerging as an important infectious disease
in North America where many human deaths have
been associated with bat rabies.2,3 The production
of vaccines, diagnosis and further research will
therefore continue in this ﬁeld.
Inactivation of this highly neurotropic virus is es-
sential for the preparation of vaccines, diagnos-
tic reagents and research purposes. Currently, the
recommended inactivating agent for this virus is
beta propiolactone (BPL), which is a very expen-
sive chemical and potentially carcinogenic.4 Other
chemicals like formaldehyde and phenol not only in-
activate the virus but also adversely affect its anti-
genicity.
There is therefore a need to ﬁnd alternative inac-
tivating agents which are not expensive and are eas-
ily available. It was demonstrated by Turner et al.
that ascorbic acid undergoing auto oxidation cat-
alyzed by cupric ions inactivated vaccinia virus.5
Subsequently this was conﬁrmed with other DNA
and RNA viruses and it was also shown that the inac-
tivated viruses retained good antigenicity.6 Recent
studies have shown that this agent could also in-
activate HIV7 and bacteriophages8 and interest has
been renewed for using this chemical as an antiviral
agent.
Keeping this in mind the effect of ascorbic acid
on the rabies virus was investigated and the studies
here indicate that this chemical along with cupric
ions is capable of causing complete and irreversible
inactivation of ﬁxed rabies virus without adversely
affecting the antigenicity.
Materials and methods
Virus material
The Vero cell adapted challenge virus strain (CVS
13, obtained from the Central Research Institute,
Kasauli, India) was grown in Roux bottles on a mono
layer of Vero cells (ATCC, CCL81, obtained from the
National Center for Cell Science, Pune, India) by
using standard procedures.9 The infectivity titer of
the virus was determined by intracerebral inocula-
tion of young mice using a standard procedure.10
The titer was calculated by the method of Reed
and Muench.11 Thus a stock virus material having
a titer of 107 MICLD50 (50% mouse lethal dose)
per ml was prepared, aliquoted, and stored at
−75 ◦C.
Chemicals and virus treatment
Ascorbic acid and copper sulfate were procured
from Sigma Chemicals (USA). Stock solutions con-
taining 0.1M of copper sulfate and 0.5M of ascorbic
acid were prepared in sterile distilled water and
sterilized by membrane ﬁltration. The stock solu-
tions were added to the virus suspension to obtain
a ﬁnal concentration of 5g/ml of copper sulfate
and three increasing concentrations of ascorbate
i.e. 0.1mg/ml, 0.5mg/ml and 1mg/ml. The con-
trols consisted of virus suspension to which equal
volumes of sterile PBS (pH 7.2) was added. The
test and the control virus material were kept at
4 ◦C. An aliquot was taken every 24 hours for seven
days. There was no signiﬁcant change in the pH of
the virus material after addition of the chemicals.
Determination of infectivity titers
Each aliquot was titrated for viral infectivity using
both mice inoculation10 and titration in Vero cells
using the ﬂuorescent focus method in 96 well tissue
culture plates.12 Vero cells were grown as monolay-
ers in the wells of the plate and 100l each of ten
fold dilutions of virus material were added to each
well, incubated for 1 hour at 37 ◦C after which fresh
medium was added. The plates were further incu-
bated for 72 hours in a CO2 incubator after which
the cells were stained for immunoﬂuorescence us-
ing rabies conjugate (obtained from the Central Re-
search Institute, Kasauli, India). The plates were
observed under a ﬂuorescence microscope (Leitz)
and the highest dilution of virus showing ﬂuorescent
foci in 50% of the microscopic ﬁeld was noted. The
exact titer was calculated by the Reed and Muench
method.
For the inoculation, female four-week old Swiss
albino mice were procured from the Central Ani-
mal Research Facility, NIMHANS. The animals were
housed and looked after as per the regulations and
permission to conduct the study was obtained from
the Institutional Ethics Committee for experimen-
tation on animals.
A mouse LD50 titer of each aliquot was calculated
by the Reed and Muench method after a 14-day ob-
servation of the inoculated mice. The ﬂuorescent
focus units (FFU/ml) titer was calculated after
staining the Vero cells in the tissue culture plate
with FITC rabies conjugate (obtained from the
Central Research Institute, Kasauli) using standard
procedures. The end point dilution showing 50%
ﬂuorescent foci in the well was noted and the titer
calculated by the Reed and Muench method. The
infectivity titers of aliquots kept at −75 ◦C were
also determined in parallel.
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Studies to determine the antigenicity
Preliminary experiments had shown that treatment
of the virus with 0.5mg/ml of ascorbic acid for 72
hours completely inactivated it. Therefore, to de-
termine the antigenicity of the inactivated virus we
used virus material inactivated with 0.5mg/ml of
ascorbic acid and 5g/ml of copper sulfate. We
determined the antigenicity of the virus material
both by the induction of antibodies in experimental
mice and by the mouse protection test. As a con-
trol we used the same viral harvest inactivated by
BPL (Sigma Chemicals) at a concentration of 1:4000
kept for 72 hours at 4 ◦C.
Groups of eight mice were inoculated intraperi-
toneally with two 0.5ml doses of either ascorbic
acid or BPL inactivated virus material at one-week
intervals. They were then bled by the retro orbital
route one week later, after a light anesthesia with
ether. The sera were separated and inactivated at
56 ◦C for 30 minutes and kept frozen pending anti-
body titration by the rapid ﬂuorescent focus inhibi-
tion test (RFFIT).
The RFFIT was performed as per the WHO recom-
mended procedure13 but with some modiﬁcation.
Instead of Labtek chambers, 96 well tissue culture
plates were used and the cell line used was BHK
21, CL 13 (obtained from the National Center for
Cell Science, Pune). The challenge virus used was
CVS adapted to BHK 21 cell line and having a titer
of 10 7.8/ml when titrated in BHK 21 cells. For
the test, 50LD50 of the challenge virus was used.
The antibody titers were expressed as the recip-
rocal of the 50% end point dilution calculated by
the method used by Reed and Muench. The titers
were expressed in IU/ml so as to compare to a na-
tional standard of rabies immune globulin (RIG) with
a potency of 80 IU/ml when previously calibrated
against the ﬁrst WHO international reference RIG.
Table 1 The effect of ascorbic acid and Cu2+ on the infectivity titer of the vero cell grown CVS strain of the
rabies virus as determined by intracerebral inoculation of mice.
Virus suspension Infectivity titer (Log MICLD50/ml) at the end of day
1 2 3 4 5 6 7
Ascorbic acid treated
0.1mg/ml 7.0 7.2 7.0 7.0 6.5 6.5 6.0
0.5mg/ml 7.0 4.5 0 0 0 0 0
1mg/ml 7.0 3.5 0 0 0 0 0
Virus control
At 4 ◦C 7.0 7.0 6.8 6.8 6.9 6.5 6.0
At −75 ◦C 7.0 7.2 7.0 7.5 7.0 7.2 7.0
MICLD50 = Mouse intracerebral 50% lethal dose.
Modiﬁed NIH test
The antigenicity of the inactivated virus material
was also determined by the NIH test14 with some
modiﬁcations. Groups of eight mice were inocu-
lated intraperitoneally with 0.5ml of 5 fold dilu-
tions (1:5 to 1:3125) of both BPL and ascorbic inac-
tivated virus material at one-week intervals. They
were then challenged a week later with 50LD50 of
CVS and observed for 14 days. The survival:death
ratio in each dilution was noted and the 50% per-
cent effective dose (ED50) was calculated by the
Reed and Muench method. The antigenicity in terms
of potency was calculated so as to compare to a
national reference standard previously calibrated
against the ﬁfth international standard of rabies
vaccine (procured from WHO) having a potency of
16 IU per ampoule.
Results
Effects of ascorbic acid on virus infectivity
We tested the inactivating property of three con-
centrations of ascorbic acid keeping the concentra-
tion of copper sulfate constant. In the titers ob-
tained by the mice inoculation and tissue culture
method, there was only one log that was higher than
the others.
Complete loss of infectivity of the virus treated
by both methods with 0.5mg/ml of ascorbic acid
was evident at the end of the 72 hours (see Tables 1
and 2). With a 0.1mg/ml concentration of ascorbic
acid there was no appreciable reduction in the in-
fectivity titer which remained at 106 at the end of
seven days and did not differ signiﬁcantly with the
titer of virus control kept at 4 ◦C. With a concentra-
tion of 1mg/ml the infectivity titer (both by mice
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Table 2 The effect of ascorbic acid and Cu2+ on the infectivity titer of the Vero cell grown CVS as determined
by the ﬂuorescent focus method using Vero cells.
Virus suspension Infectivity titer (FFU/ml) at the end of day
1 2 3 4 5 6 7
Ascorbic acid treated
0.1mg/ml 6.2 6.5 6.0 6.2 6.0 5.8 5.5
0.5mg/ml 6.0 4.2 0 0 0 0 0
1.0mg/ml 6.0 3.5 0 0 0 0 0
Virus control
4 ◦C 6.2 6.5 6.0 6.0 6.0 5.6 5.0
−75 ◦C 6.5 6.2 6.2 6.5 6.0 6.0 6.0
FFU/ml = Fluorescent focus units/ml.
inoculation and infection in cell culture) dropped
from 107/ml to 103.5/ml at the end of 24 hours and
became zero at the end of 48 hours. However, with
this concentration the pH of the medium became
acidic (from pH 7.4 to pH 6.5). With a concentration
of 0.5mg/ml of ascorbic acid the infectivity titer
fell slowly compared to the higher concentration
but complete inactivation was noticed at the end of
72 hours. There was no signiﬁcant change in the pH.
Therefore, for all future experiments, an ascorbic
acid concentration of 0.5mg/ml was ﬁxed.
Induction of neutralizing antibodies in mice
Both ascorbic acid and BPL inactivated virus mate-
rial induced comparable levels of neutralizing an-
tibodies as evidenced by RFFIT (Table 3). Groups
of eight mice were inoculated with the inactivated
virus material and a very good neutralizing antibody
response was obtained in all the mice inoculated.
The geometricmean titer (GMT) of the ascorbic acid
inactivated virus was 3.5 IU/ml and that of BPL in-
activated virus was 3.2 IU/ml and so they did not
differ signiﬁcantly.
Potency
To further conﬁrm the antigenicity of the inacti-
vated virus material, a modiﬁed NIH test was per-
Table 3 Neutralizing antibody titers (IU/ml) in mice inoculated with BPL and the ascorbic acid inactivated rabies
virus.
Virus type RFFIT titers (IU/ml) in mice numbered GMT
1 2 3 4 5 6 7 8
BPL inactivated 2.4 3.2 3.5 2.8 3.4 2.4 2.7 3.4 3.2
Ascorbic acid inactivated 3.4 2.8 3.2 2.5 2.9 3.2 3.2 2.9 3.5
RFFIT = Rapid ﬂuorescent focus inhibition test, GMT= Geometric mean titer.
Table 4 The ED50 and antigenic potency of BPL and
ascorbic acid inactivated virus material as determined
by a modiﬁed NIH test.
Virus material ED50 Potency
Ascorbic acid inactivated 1:625 3.5 IU/ml
BPL inactivated 1:700 3.8 IU/ml
ED50 = 50% effective dose.
formed, which involved the immunization of mice
with the inactivated virus followed by a lethal chal-
lenge with the live virus. It is evident from the re-
sults of the modiﬁed NIH test that the ED50 of both
ascorbic acid and BPL inactivated virus materials
did not differ signiﬁcantly and the potency values
obtained were comparable to a reference vaccine
(Table 4).
Discussion
Earlier experiments by Turner et al.5 and more re-
cent studies by Rawal et al.6,7 have indicated that
ascorbic acid can be used as an inactivating agent
for both RNA and DNA viruses. To our knowledge this
is the ﬁrst controlled study to investigate the inac-
tivating property of these chemicals on the rabies
virus.
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The minimum effective concentration of ascor-
bic acid was found to be 0.5mg/ml and at this
concentration there was no signiﬁcant fall in pH.
Increasing the concentration to 1mg/ml resulted
in signiﬁcant fall in pH and this caused a slough-
ing of Vero cells during titration. A concentration
of 0.5mg/ml was therefore used in all following
experiments to determine the antigenicity of the
inactivated virus. At this concentration there was
complete and irreversible inactivation of the virus
at the end of 72 hours.
The virus remained non-infectious at the end of
seven days. One of the criteria for selecting an in-
activating agent for any virus (unless for therapeu-
tic purposes) is that it should not adversely affect
the antigenicity of the virus so that the inactivated
virus could be used as a vaccine or for any other
research purpose.
Additionally, the rabies virus is highly neurotropic
and can cause fatal encephalitis and so necessary
precautions should be taken while handling the
virus and unless indicated the live virus should not
be handled in routine laboratories. As the use of
BPL is very expensive, cheaper chemicals need to
be evaluated for their inactivating properties.
Results of the present study indicate that ascorbic
acid, which is not only inexpensive but also easily
available, is found to be suitable for this purpose.
The mechanism by which ascorbic acid inac-
tivates viruses is not very clear. A recent study
by Murata et al.8 has shown that the presence
of oxygen is essential and ascorbic acid under-
going auto-oxidation results in the formation of
OH groups that could bring about the inactivation
of the cell free viruses. It remains to be estab-
lished whether ascorbic acid could inactivate cell
associated viruses. This will be of great interest
particularly if ascorbic acid is considered as a po-
tential therapeutic agent. Indeed, in a study by
Gode et al.15 the lives of two rabies patients were
prolonged with the administration of high doses of
ascorbic acid. Another possibility is its potential
for local wound inﬁltration in order to inactivate
the virus deposited after animal bites, especially in
view of the fact that there may be global shortage
of rabies immunoglobulins in the near future.16
Conclusion
It has been demonstrated that ascorbic acid has a
potential for being used as an inactivating agent
for the rabies virus without adversely affecting its
antigenicity. Further studies are required to deter-
mine whether it is feasible to use this chemical for
the production of inactivated rabies vaccines and
whether it has therapeutic potential for treating ra-
bies patients.
Conﬂict of interest: No conﬂicting interest de-
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